Gene Therapy: Curing Genetic Diseases With a Single Treat...

Innovation & Technology · 2 · November 26, 2025

Zolgensma, the gene therapy for spinal muscular atrophy, costs $2.1 million for a single dose — making it the second most expensive drug in history (behind Hemgenix at $3.5 million for hemophilia B). These prices are forcing families to look internationally for access.

FDA-Approved Gene Therapies and Their Prices

Zolgensma (SMA): $2.1 million, single IV infusion for infants. Luxturna (inherited retinal dystrophy): $850,000 for both eyes. Hemgenix (hemophilia B): $3.5 million, single dose. Skysona (cerebral adrenoleukodystrophy): $3 million. Casgevy and Lyfgenia (sickle cell disease): $2.2 million and $3.1 million respectively. These are one-time treatments that aim to cure previously incurable genetic conditions — the economics of gene therapy pricing are fundamentally different from chronic drug therapies.

International Access at Lower Cost

India's Zolgensma access program, facilitated through Novartis's managed access pathway, has treated over 100 SMA patients at significantly reduced cost — approximately $200,000-$400,000 versus $2.1 million in the US. This isn't a biosimilar or knockoff — it's the identical product at a country-specific negotiated price.

China has approved its own SMA gene therapy (Xiaoailingna/rAAV9-SMN1) at approximately $280,000 — the first domestically manufactured gene therapy for SMA. Brazil and Turkey have also established government-funded access programs for Zolgensma at negotiated prices 70-90% below US list price.

The Future: Gene Editing (CRISPR)

Casgevy, approved in 2023, was the first CRISPR-based therapy — editing patients' own stem cells to produce functional hemoglobin for sickle cell disease. CRISPR therapies in development: CRISPR-Cas9 for beta-thalassemia, Duchenne muscular dystrophy, transthyretin amyloidosis, and hereditary angioedema. The manufacturing cost of CRISPR therapies is expected to drop significantly as the technology matures — potentially bringing gene therapy prices below $500,000 within 5-10 years.

Key Takeaways

- Gene therapy prices range from $850,000 to $3.5 million per treatment in the US

- India's Zolgensma access program offers the same therapy at $200,000-$400,000

- China approved a domestically manufactured SMA gene therapy at ~$280,000

- CRISPR-based therapies are expected to reduce gene therapy manufacturing costs significantly

Compare real-time pricing using our global cost calculator.